Both are obviously a gamble, but pharma is more of a black box than tech.
As an investor, I can make an informed option whether there is a market for subscription indoor cycles like an Peloton. I could be wrong, but I can look up the market numbers and weigh them against my personal experience and world view. When it comes to pharma, almost nobody has domain expertise of the subject.
To put it another way, the leading risk in tech is market adoption, while the leading risk pin Biopharma is technical feasibility.
As an investor, I can make an informed option whether there is a market for subscription indoor cycles like an Peloton. I could be wrong, but I can look up the market numbers and weigh them against my personal experience and world view. When it comes to pharma, almost nobody has domain expertise of the subject.
To put it another way, the leading risk in tech is market adoption, while the leading risk pin Biopharma is technical feasibility.